LONDON, UK - 23 October, 2007 -- SkyePharma PLC (LSE: SKP) announces that Mylan Inc. (NYSE: MYL) and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (LSE: GSK) (“GSK”) relating to Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GSK’s Paxil CR(R). All litigation between Mylan and GSK relating to Paroxetine HCl ER Tablets has been dismissed.
